Last reviewed · How we verify
Acalabrutinib Treatment B
Acalabrutinib Treatment B is a Small molecule drug developed by AstraZeneca. It is currently in Phase 1 development. Also known as: Acalabrutinib capsule.
At a glance
| Generic name | Acalabrutinib Treatment B |
|---|---|
| Also known as | Acalabrutinib capsule |
| Sponsor | AstraZeneca |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (PHASE2)
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma (PHASE1, PHASE2)
- Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure (PHASE4)
- Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (PHASE2)
- Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (PHASE2)
- ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic Leukemia (PHASE1, PHASE2)
- Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas (PHASE2)
- Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acalabrutinib Treatment B CI brief — competitive landscape report
- Acalabrutinib Treatment B updates RSS · CI watch RSS
- AstraZeneca portfolio CI
Frequently asked questions about Acalabrutinib Treatment B
What is Acalabrutinib Treatment B?
Acalabrutinib Treatment B is a Small molecule drug developed by AstraZeneca.
Who makes Acalabrutinib Treatment B?
Acalabrutinib Treatment B is developed by AstraZeneca (see full AstraZeneca pipeline at /company/astrazeneca).
Is Acalabrutinib Treatment B also known as anything else?
Acalabrutinib Treatment B is also known as Acalabrutinib capsule.
What development phase is Acalabrutinib Treatment B in?
Acalabrutinib Treatment B is in Phase 1.
Related
- Manufacturer: AstraZeneca — full pipeline
- Also known as: Acalabrutinib capsule
- Compare: Acalabrutinib Treatment B vs similar drugs
- Pricing: Acalabrutinib Treatment B cost, discount & access